Skip to main content
Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation

Fig. 5

RTX was effective to conventional immunosuppressants in patients with excessive B cell differentiation. a Rate of improvement in BVAS after 6 months of induction therapy in patients with and without excessive B cell differentiation by treatment group. Data show the median rate of improvement in BVAS. **p < 0.05, *p < 0.01 according to Bonferroni method. b Rate of remission after 6 months of induction therapy in patients with excessive B cell differentiation by treatment group. *p < 0.01 according to Fisher’s exact test. c Changes in BVAS after 6 months of induction therapy in patients with and without excessive B cell differentiation by treatment group. Data are mean ± SD of BVAS in each group. d Differences between RTX and IV-CY groups in survival rates after 6 months of induction therapy in patients with excessive B cell differentiation

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us